Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis

被引：1
|
作者：
Colombel, Jean-Frederic [1 ]
Sandborn, William [2 ]
Wolf, Doug [3 ]
Panaccione, Remo [4 ]
Lazar, Andreas [5 ]
Kron, Martina [5 ]
Robinson, Anne [6 ]
Thakkar, Roopal [6 ]
机构：
[1] CHRU, Hop Huriez, Lille, Nord, France
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Atlanta Gastroenterol Associates, Atlanta, GA USA
[4] Univ Calgary, Calgary, AB, Canada
[5] Abbott GmbH & Co KG, Ludwigshafen, Germany
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2012年 / 18卷
关键词：
D O I：
10.1097/00054725-201212001-00052
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 50 条
  • [41] A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
    Aoun, Roni
    Hanauer, Stephen
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (05) : 411 - 423
  • [42] Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
    Ernest-Suarez, Kenneth
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [43] Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
    Reinisch, Walter
    Sandborn, William J.
    Hommes, Daniel W.
    D'Haens, Geert
    Hanauer, Stephen
    Schreiber, Stefan
    Panaccione, Remo
    Fedorak, Richard N.
    Tighe, Mary Beth
    Huang, Bidan
    Kampman, Wendy
    Lazar, Andreas
    Thakkar, Roopal
    GUT, 2011, 60 (06) : 780 - 787
  • [44] Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
    Diakite, I.
    Schultz, B.
    Carter, J.
    Snedecor, S.
    Turpin, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S454 - S455
  • [45] Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
    Iborra, Marisa
    Alvarez-Sotomayor, Diego
    Nos, Pilar
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 39 - 46
  • [46] Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
    Schultz, Bob G.
    Diakite, Ibrahim
    Carter, John A.
    Snedecor, Sonya J.
    Turpin, Robin
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (11): : 1592 - 1600
  • [47] COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB SC FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Schultz, Robert
    Diakite, Ibrahim
    Carter, John A.
    Snedecor, Sonya
    Turpin, Robin S.
    GASTROENTEROLOGY, 2020, 158 (06) : S658 - S658
  • [48] Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study
    Angelison, Leif
    Almer, Sven
    Davidsdottir, Loa
    Hammarlund, Per
    Lindgren, Stefan
    Hindorf, Ulf
    Marsal, Jan
    Hertervig, Erik
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (02) : 154 - 162
  • [49] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
  • [50] Efficacy of Adalimumab in the Treatment of Ulcerative Colitis
    Garcia-Bosch, Orlando
    Aceituno, Montserrat
    Gisbert, Javier P.
    Andreu, Montserrat
    Merino, Olga
    Cabriada, Jose Luis
    Ciarcia, Valle
    Gutierrez, Aria
    Nos, Pilar
    Penalva, Mireia
    Hinojosa, Joaquin
    Garcia-Planella, Esther
    Munoz, Fernando
    Calvet, Xavier
    GASTROENTEROLOGY, 2010, 138 (05) : S696 - S696
12345